Comparison of hybrid procedure and open surgical revascularization for multilevel infrainguinal arterial occlusive disease
Occlusive
Claudication
DOI:
10.2147/cia.s66860
Publication Date:
2014-09-22T23:36:39Z
AUTHORS (7)
ABSTRACT
Objective: To compare outcomes of hybrid (combined surgical and endovascular) procedures (HYBRID) with open reconstructions (OPEN) in patients multilevel infrainguinal artery occlusive diseases. Design: Case series study retrospective analysis prospectively collected nonrandomized data. Methods: Between 2008 2012, 64 underwent OPEN 43 HYBRID. Patient characteristics, technique success, clinical improvement, procedure-related morbidity were reviewed compared. Patency rates limb salvages analyzed compared using Kaplan–Meier life tables. Cox regression analyses used to assess the influence various risk factors on primary patency. Results: HYBRID older presented worse New York Heart Association function patients. The increase ankle-brachial index improvement Ruthford category after equivalent between two groups, but had shorter hospital length stay (7.6±12.0 versus 15.5±17.3; P = 0.018) less overall perioperative (12% 28%; =0.042) No statistically significant difference 36-month (47.1%±7.1% 50.1%±9.4%; =0.418), assisted (57.0%±7.9% 62.4%±9.2%; =0.517), or secondary (82.0%±6.8% 83.1%±7.3%; =0.445) patency was seen groups. Limb salvage vs at 3 years similar (76.3%±9.3% 80.4%±8.2%; =0.579). Critical ischemia a negative predictor long-term both groups ( =0.012 <0.001, respectively), presence diabetes renal insufficiency another independent predictors decreased for =0.017 =0.019, respectively). Conclusion: Multilevel diseases could be treated by procedure, hospitalization, morbidity, early- efficacy revascularization. A procedure should considered high risk, critical ischemia, diabetes, compromise its Keywords: atherosclerotic disease, endovascular treatment
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (34)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....